MilliporeSigma To Become First Provider To Offer Fully Integrated mRNA Services

MilliporeSigma, the U.S. and Canada-based Life Science business of Merck KGaA, Darmstadt, Germany, has achieved a significant milestone as the world's first Contract Testing, Development, and Manufacturing Organization (CTDMO) to offer comprehensive, integrated services covering all critical phases of mRNA development, manufacturing, and commercialization. This achievement coincides with the inauguration of two state-of-the-art GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany, representing a €28 million investment and the creation of 75 new jobs. MilliporeSigma's commitment to advancing mRNA technologies is underpinned by an ongoing €1 billion investment and strategic acquisitions like AmpTec and Exelead. The newly opened facilities enhance the company's capacity to offer mRNA services across all scales, from pre-clinical to commercial, with a focus on analytical development and biosafety testing tailored specifically for mRNA technologi...